Deep dives, evidence grades, and clinical tools, all in one place.
Practice Signal
Alzheimer's Blood Tests: What Pharmacists Need to Know
Neurology5 sources · Updated Aug 13, 2026
Your patients are reading about blood tests that predict Alzheimer's. Here is what the evidence actually shows, where the guidelines stand, and what it means at the pharmacy counter.
Bottom Line
Plasma p-tau217 blood tests can identify Alzheimer's disease pathology with accuracy approaching PET and CSF, but they detect amyloid status, not cognitive decline. Current guidelines restrict their use to specialty settings with objective cognitive impairment, yet direct-to-consumer tests and primary care ordering are already outpacing the evidence. Pharmacists should be prepared to counsel patients on what these results do and do not mean, flag false-positive risk in patients with severe renal impairment (eGFR 30 or below), and understand that a positive result does not equal a dementia diagnosis.
0.93-0.96
AUC of p-tau217 for AD pathology across care settings
3-4 yr
Median prediction error of the plasma clock model
16+
Commercially available AD blood tests as of early 2026
eGFR <30
Renal threshold linked to false-positive p-tau217
State of Play
Blood-based biomarkers for Alzheimer's disease have moved from research curiosity to clinical reality in under two years.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Want the full review?
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.